The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Curcumin Nanoformulation for Cervical Cancer Treatment
Open accessAbstract
Cervical cancer is one of the most common cancers among women worldwide. Current standards of care for cervical cancer includes surgery, radiation and chemotherapy. Conventional chemotherapy fails to elicit therapeutic responses and causes severe systemic toxicity. Thus, developing a natural product based, safe treatment modality would be a highly viable option. Curcumin (CUR) is a well-known natural compound, which exhibits excellent anti-cancer potential by regulating many proliferative, oncogenic and chemo-resistance associated genes/proteins. However, due to rapid degradation and poor bioavailability, its translational and clinical use has been limited. To improve these clinically relevant parameters, we report a poly(lactic-co-glycolic acid) based curcumin nanoparticle formulation (Nano-CUR). This study demonstrates that in comparison to free CUR, Nano-CUR effectively inhibits cell growth, induces apoptosis and arrests the cell cycle in cervical cancer cell lines. Nano-CUR treatment modulated entities such as miRNAs, transcription factors and proteins associated with carcinogenesis. Moreover, Nano-CUR effectively reduced the tumor burden in a pre-clinical orthotopic mouse model of cervical cancer by decreasing oncogenic miRNA-21, suppressing nuclear β-catenin and abrogating expression of E6/E7 HPV oncoproteins including smoking compound benzo[a]pyrene (BaP) induced E6/E7 and IL-6 expression. These superior pre-clinical data suggest that Nano-CUR may be an effective therapeutic modality for cervical cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543
Löffler, D., Brocke-Heidrich, K., Pfeifer, G., Stocsits, C., Hackermüller, J., Kretzschmar, A. K., Burger, R., Gramatzki, M., Blumert, C., Bauer, K., et al. (2007) · Blood · doi:10.1182/blood-2007-03-081133 · Cited by 637
Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression
Heinecke, J. L., Ridnour, L. A., Cheng, R. Y. S., Switzer, C. H., Lizardo, M. M., Khanna, C., Glynn, S. A., Hussain, S. P., Young, H. A., Ambs, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401799111 · Cited by 177
Cited by
Cellular and molecular mechanisms of curcumin in prevention and treatment of disease
Patel, S. S., Acharya, A., Ray, R. S., Agrawal, R., Raghuwanshi, R., & Jain, P. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1552244 · Cited by 511
Natural product-based nanoformulations for cancer therapy: Opportunities and challenges
Kashyap, D., Tuli, H. S., Yerer, M. B., Sharma, A., Sak, K., Srivastava, S., Pandey, A., Garg, V. K., Sethi, G., & Bishayee, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.014 · Cited by 390
Niosomes: A review on niosomal research in the last decade
Bhardwaj, P., Tripathi, P., Gupta, R., & Pandey, S. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101581 · Cited by 366
Nanoformulations of curcumin: an emerging paradigm for improved remedial application
Gera, M., Sharma, N., Ghosh, M., Huynh, D. L., Lee, S. J., Min, T., Kwon, T., & Jeong, D. K. (2017) · Oncotarget · doi:10.18632/oncotarget.19164 · Cited by 354
MicroRNA: A novel target of curcumin in cancer therapy
Mirzaei, H., Masoudifar, A., Sahebkar, A., Zare, N., Sadri Nahand, J., Rashidi, B., Mehrabian, E., Mohammadi, M., Mirzaei, H. R., & Jaafari, M. R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26055 · Cited by 236
Metadata
- Authors
- Zaman, M. S., Chauhan, N., Yallapu, M. M., Gara, R. K., Maher, D. M., Kumari, S., Sikander, M., Khan, S., Zafar, N., Jaggi, M., & Chauhan, S. C.
- Venue
- Scientific Reports
- Published
- 2016-02-03
- Volume
- 6
- Issue
- 1
- Pages
- 20051-20051
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2261551157
- Cited by
- 205
- References
- 3
- FWCI
- 10.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.